research use only

Acelarin (NUC-1031) DNA/RNA Synthesis inhibitor

Cat.No.S9649

Acelarin (NUC-1031, CPF-31, MTL-007, GTPL7389) is a DNA synthesis inhibitor with EC50 of 0.2 nM.
Acelarin (NUC-1031) DNA/RNA Synthesis inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 580.47

Quality Control

Batch: S964901 DMSO]100 mg/mL]false]Ethanol]20 mg/mL]false]Water]Insoluble]false Purity: 99.84%
99.84

Chemical Information, Storage & Stability

Molecular Weight 580.47 Formula

C25H27F2N4O8P

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 840506-29-8 -- Storage of Stock Solutions

Synonyms CPF-31, MTL-007, GTPL7389 Smiles CC(C(=O)OCC1=CC=CC=C1)NP(=O)(OCC2C(C(C(O2)N3C=CC(=NC3=O)N)(F)F)O)OC4=CC=CC=C4

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (172.27 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 20 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
DNA synthesis [1]
(Cell-free assay)
0.2 nM(EC50)
In vitro

Acelarin (NUC-1031) is a prodrug with potent cytostatic activity in a range of different tumor cell lines. Importantly, its activation is significantly less dependent on deoxycytidine kinase and on nucleoside transporters, and it is resistant to cytidine deaminase-mediated degradation.[1]

In vivo

In pancreatic cancer xenografts, Acelarin (NUC-1031) shows a significant reduction in tumor volumes in vivo.[1]

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02351765 Completed
Biliary Tract Cancer|Gallbladder Cancer|Cholangiocarcinoma|Ampullary Cancer
The Christie NHS Foundation Trust
January 2016 Phase 1
NCT02303912 Completed
Recurrent Ovarian Cancer
Imperial College Healthcare NHS Trust
November 2014 Phase 1
NCT01621854 Completed
Cancer
Imperial College London|Nucana
October 2012 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map